| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7907135 | LIFE MOLECULAR | Image display and image displaying method for gradation correction |
Mar, 2029
(4 years from now) | |
| US7807135 | LIFE MOLECULAR | Stilbene derivatives and their use for binding and imaging amyloid plaques |
Mar, 2029
(4 years from now) | |
Neuraceq is owned by Life Molecular.
Neuraceq contains Florbetaben F-18.
Neuraceq has a total of 2 drug patents out of which 0 drug patents have expired.
Neuraceq was authorised for market use on 19 March, 2014.
Neuraceq is available in solution;intravenous dosage forms.
Neuraceq can be used as neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment.
Drug patent challenges can be filed against Neuraceq from 21 March, 2018.
The generics of Neuraceq are possible to be released after 18 March, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 21, 2019 |
Drugs and Companies using FLORBETABEN F-18 ingredient
NCE-1 date: 21 March, 2018
Market Authorisation Date: 19 March, 2014
Treatment: Neuraceq is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to estimate p-amyloid neuritic plaque density in adult patients with cognitive impairment
Dosage: SOLUTION;INTRAVENOUS
NEURACEQ family patents
